We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

090430:KRXAmorepacific Corporation Analysis

Data as of 2026-03-15 - not real-time

₩131,000.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Amorepacific is trading at 131,000 KRW, comfortably above its 20‑day SMA (≈145,985) and 50‑day SMA (≈135,368), confirming a short‑term bullish bias, while the 200‑day SMA (≈129,145) also lies below the current price, supporting a longer‑term uptrend. However, the MACD histogram remains deeply negative and the MACD line is well under the signal line, signaling bearish momentum in the near term. The RSI sits at about 40, indicating the stock is not yet oversold but also not in overbought territory. Volatility is high at roughly 72% over the past 30 days, yet the computed beta of ~0.34 suggests the share moves less than the market, tempering systematic risk. Fundamentally, revenue grew 4.1% YoY with a robust gross margin of 72% and operating margin near 9%, pointing to solid profitability. Cash on hand (≈872 bn KRW) more than doubles total debt (≈339 bn KRW), giving the company a comfortable net‑cash position. The dividend yield of 0.95% coupled with a payout ratio under 50% makes the payout appear sustainable. A DCF‑derived fair value of roughly 118,800 KRW places the current price about 10% above intrinsic value, implying limited upside in the short run but still room for upside relative to analyst targets near 169,000 KRW. Overall, the stock sits in a bullish technical environment with mixed momentum signals and appears modestly overvalued against intrinsic estimates, while fundamentals and dividend sustainability remain strong.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram indicating near‑term momentum weakness
  • Price above key moving averages supporting bullish bias
  • High 30‑day volatility suggesting price swings

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustained cash surplus and manageable debt levels
  • Strong brand portfolio with steady revenue growth
  • Analyst target prices implying ~30% upside

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Consistent profitability and high gross margins
  • Dividend yield with sub‑50% payout ratio
  • Consumer‑defensive sector positioning offering resilience

Key Metrics & Analysis

Financial Health

Revenue Growth4.10%
Profit Margin3.78%
P/E Ratio20.0
ROE3.31%
ROA3.36%
Debt/Equity6.25
Op. Cash Flow₩530.6B
Free Cash Flow₩472.6B

Technical Analysis

TrendBullish
RSI40.5
Support₩122,000.00
Resistance₩166,000.00
MA 20₩145,985.00
MA 50₩135,368.00
MA 200₩129,144.50
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Fair Value₩118,809.48
Target Price₩169,333.33
Upside/Downside29.26%
GradeOvervalued
TypeBlend
Dividend Yield0.95%

Risk Assessment

Beta0.34
Volatility72.08%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.